Liana Moussatos
Stock Analyst at Wedbush
(4.65)
# 142
Out of 4,479 analysts
45
Total ratings
58.49%
Success rate
33.89%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLSD Clearside Biomedical | Maintains: Outperform | $5 → $4 | $1.23 | +225.20% | 2 | Mar 13, 2024 | |
| VRNA Verona Pharma | Reiterates: Outperform | $33 | $15.46 | +113.45% | 6 | Mar 1, 2024 | |
| UTHR United Therapeutics | Reiterates: Outperform | $308 | $317.05 | -2.85% | 6 | Feb 22, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $75 | $110.36 | -32.04% | 4 | May 23, 2023 | |
| LQDA Liquidia | Downgrades: Underperform | $4 → $3 | $11.83 | -74.64% | 3 | Sep 1, 2022 | |
| ASND Ascendis Pharma | Maintains: Outperform | $128 → $117 | $136.27 | -14.14% | 3 | Mar 3, 2022 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $97 → $94 | $22.74 | +313.37% | 4 | Feb 28, 2022 | |
| XOMA XOMA Corporation | Downgrades: Neutral | n/a | $24.64 | - | 3 | Sep 7, 2021 | |
| AVTE Aerovate Therapeutics | Initiates: Outperform | n/a | $1.62 | - | 1 | Jul 26, 2021 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Neutral | n/a | $1.60 | - | 2 | Jan 29, 2021 | |
| IMUX Immunic | Initiates: Outperform | n/a | $1.15 | - | 1 | Jun 5, 2020 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | n/a | $82.22 | - | 4 | Mar 2, 2020 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | n/a | $2.42 | - | 3 | Feb 10, 2020 | |
| RGLS Regulus Therapeutics | Downgrades: Neutral | n/a | $1.76 | - | 3 | Jul 10, 2018 |
Clearside Biomedical
Mar 13, 2024
Maintains: Outperform
Price Target: $5 → $4
Current: $1.23
Upside: +225.20%
Verona Pharma
Mar 1, 2024
Reiterates: Outperform
Price Target: $33
Current: $15.46
Upside: +113.45%
United Therapeutics
Feb 22, 2024
Reiterates: Outperform
Price Target: $308
Current: $317.05
Upside: -2.85%
Blueprint Medicines
May 23, 2023
Reiterates: Outperform
Price Target: $75
Current: $110.36
Upside: -32.04%
Liquidia
Sep 1, 2022
Downgrades: Underperform
Price Target: $4 → $3
Current: $11.83
Upside: -74.64%
Ascendis Pharma
Mar 3, 2022
Maintains: Outperform
Price Target: $128 → $117
Current: $136.27
Upside: -14.14%
Pacira BioSciences
Feb 28, 2022
Maintains: Outperform
Price Target: $97 → $94
Current: $22.74
Upside: +313.37%
XOMA Corporation
Sep 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $24.64
Upside: -
Aerovate Therapeutics
Jul 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.62
Upside: -
Lexicon Pharmaceuticals
Jan 29, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.60
Upside: -
Immunic
Jun 5, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.15
Upside: -
BioMarin Pharmaceutical
Mar 2, 2020
Maintains: Outperform
Price Target: n/a
Current: $82.22
Upside: -
Aquestive Therapeutics
Feb 10, 2020
Maintains: Outperform
Price Target: n/a
Current: $2.42
Upside: -
Regulus Therapeutics
Jul 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $1.76
Upside: -